This admixture of cells predominantly consists of polyclonal, mostly tumor-specific CD8+ and CD4+ T cells which can bind to multiple TAAs and overcome the tumor heterogeneity and antigen escape [54]. This evidence concerns the gene CD8A and neoplasm.